Schrödinger, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Ramy Farid
- Full Time Employees
- 850
- Sector
- Technology
- Industry
- Software - Application
- Address
- 1540 Broadway New York NY United States of America 10036
- IPO Date
- Feb 5, 2020
- CIK
- 0001490978
- Website
- schrodinger.com
- Similar Companies
- Business
- Schrödinger, Inc. (SDGR) develops physics-based computational platforms that accelerate the discovery of novel molecules for drug development and materials applications. The company offers a comprehensive suite of software products and services, including its flagship Schrödinger Platform comprising physics-based simulation software such as LiveDesign for collaborative design, Desmond and FEP+ for molecular dynamics and free energy perturbation calculations; Maestro for molecular visualization and modeling; and the Materials Science Suite for property prediction and optimization; alongside cloud-based services like Schrödinger Cloud for scalable computations, consulting services for custom model development, and enterprise solutions integrating AI-driven predictions with proprietary datasets. Founded in 1990 and headquartered in New York, the company primarily serves the biopharmaceutical, biotechnology, and chemical industries, with customers spanning North America, Europe, and Asia-Pacific regions, including major players like Pfizer, Takeda, and Novartis. In recent developments within the last two years, Schrödinger expanded its offerings through strategic collaborations, such as enhanced partnerships with biotech firms for AI-hybrid drug discovery pipelines, and continued investment in machine learning integrations to its platform amid growing demand for computational efficiency in R&D.
Company News
Schrodinger, Inc. $SDGR Shares Newly Purchased by Counterpoint Mutual Funds LLC
Schrödinger Research Published in Nature Reveals New Insights into Lithium-Ion Battery Chemistry
Reviewing Claritev (NYSE:CTEV) and Schrodinger (NASDAQ:SDGR)
Analyzing Teladoc Health (NYSE:TDOC) & Schrodinger (NASDAQ:SDGR)
Schrodinger Inc (SDGR) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 72/100
Schrodinger (SDGR) Surges 7.6%: Is This an Indication of Further Gains?
Schrödinger: Company Creation Is Now The Real Drug Business
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger, Inc. (SDGR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Schrodinger (SDGR) Soars 12.1%: Is Further Upside Left in the Stock?
AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033
Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs
Jupiter Topco LLC Acquires Shares of 28,299 Schrodinger, Inc. $SDGR
Schrödinger to Present at Morgan Stanley Global Healthcare Conference
BlackRock Inc. Buys New Shares in Schrodinger, Inc. $SDGR
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
Schrodinger Inc (SDGR) Stock Down 4.8% -- Now Undervalued? GF Score: 73/100
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Critical Review: Schrodinger (NASDAQ:SDGR) versus Weave Communications (NYSE:WEAV)